Humana (HUM) to Release Quarterly Earnings on Wednesday

Humana (NYSE:HUM - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, April 30th. Analysts expect the company to announce earnings of $9.95 per share and revenue of $32.00 billion for the quarter. Humana has set its FY 2025 guidance at 16.250-16.250 EPS.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, analysts expect Humana to post $16 EPS for the current fiscal year and $13 EPS for the next fiscal year.

Humana Price Performance

Shares of HUM traded down $1.32 during trading hours on Monday, hitting $263.08. 1,717,256 shares of the company were exchanged, compared to its average volume of 1,747,101. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a market cap of $31.75 billion, a price-to-earnings ratio of 26.44, a P/E/G ratio of 2.05 and a beta of 0.62. The firm's fifty day moving average is $266.31 and its 200 day moving average is $270.84.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a dividend yield of 1.35%. Humana's payout ratio is 35.58%.

Institutional Trading of Humana

An institutional investor recently bought a new position in Humana stock. Revolve Wealth Partners LLC acquired a new position in Humana Inc. (NYSE:HUM - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 798 shares of the insurance provider's stock, valued at approximately $202,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on HUM. StockNews.com upgraded Humana from a "hold" rating to a "buy" rating in a report on Monday, April 7th. Barclays lifted their target price on shares of Humana from $270.00 to $322.00 and gave the company an "equal weight" rating in a research report on Friday, April 11th. Guggenheim began coverage on Humana in a research report on Wednesday, April 9th. They set a "buy" rating and a $326.00 price target on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. Finally, Mizuho boosted their price target on Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $284.90.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.